Go BACK

OUH STUDIES

Studies currently being run within Oxford University Hospitals NHS Foundation Trust.

Showing 601 - 610 of 763 studies

A feasibility study of Remote Patient-Reported Outcome measures in Mitochondrial disease and Spinocerebellar ataxias (R-PROMS)

Cancer and neoplasms

A Phase 1, open-label, multicenter, dose-escalation and cohort expansion study of OKN4395, a dual antagonist of EP2 and EP4 prostanoid receptors, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors (INVOKE Trial (OKN-4395-121))

Cancer and neoplasms

A Phase 3, Randomized, Open-label, Multicenter Clinical Study to Evaluate the Safety and Efficacy of MK-1084 with FOLFOX plus Cetuximab versus FOLFOX with or without Bevacizumab as First-line Treatment of Participants with KRAS G12C Mutant, Metastatic Colorectal Cancer

Cancer and neoplasms

A Phase II/III, multisite, randomized master protocol for a global trial of BNT327 in combination with chemotherapy and other investigational agents in first-line non-small cell lung cancer

Establishment of a research register for patients and families of inherited cardiac condition/cardiomyopathy services (GenetICC)

Synergy Digital Health Assessing the relationship between everyday physical activity and exercise capacity in patients with a Fontan circulation

Cancer and neoplasms

Safety, Tolerability, Pharmacokinetics, and Antitumour Activity of WEF-001 in participants with KRAS-Mutant Advanced Solid Tumours (WEF-001-01)

A Multi-Country Observational Chart Review Study to Characterize Treatment Patterns and Clinical Outcomes among Patients with Resectable Gastric or Gastroesophageal Junction Cancer (GALERAS)

Eye

A Phase 1/2, First-in-Human, Open-label, Assessor-Masked, Randomized, Controlled, Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects with Stargardt Disease (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ATP Binding Cassette Subfamily A Member 4 (ABCA4) Gene (ASTRA)

Cancer and neoplasms

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating The Efficacy And Safety Of Inavolisib Plus A Cdk4/6 Inhibitor And Letrozole Versus Placebo Plus A Cdk4/6 Inhibitor And Letrozole In Patients With Endocrine-Sensitive Pik3ca-Mutated, Hormone Receptor-Positive, Her2-Negative Advanced Breast Cancer (INAVO123)